GO
Loading...

Medicine

More

  • HYATTSVILLE, Md., April 1- Mannkind Corp's inhaled diabetes drug Afrezza is safe and effective for diabetes patients with either the type 1 or type 2 form of the disease, U.S. health advisers said on Tuesday in recommending its approval for sales in the United States.

  • March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. Curis acquired the license to develop and market the treatment from Genentech, a unit of the Roche Holding AG, for an upfront payment of $9.5 million in November 2012.

  • WASHINGTON, March 31- Bariatric weight loss surgery on obese patients with type 2 diabetes helped many to get their blood sugar to healthy levels and to no longer require any diabetes medicines, including insulin, three years after the procedure, according to data presented at a major medical meeting on Monday.

  • WASHINGTON, March 31- Bariatric weight loss surgery on obese patients with type 2 diabetes helped many to get their blood sugar to healthy levels and to no longer require any diabetes medicines, including insulin, three years after the procedure, according to data presented at a major medical meeting on Monday.

  • FDA allows Curis to resume testing cancer drug Monday, 31 Mar 2014 | 7:44 AM ET

    March 31- Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial. The company's shares jumped about 22 percent to $3.35 in trading before the bell. The Lexington, Massachusetts- based company's shares closed at $2.75 on the Nasdaq on Friday.

  • Prana says drug fails Alzheimer's disease study Monday, 31 Mar 2014 | 6:26 AM ET

    March 31- Prana Biotechnology Ltd said its experimental drug to treat Alzheimer's disease failed to meet the main goal of a mid-stage study in patients with a mild form of the condition. The company's shares fell about 38 percent to $6.13 in premarket trade on Monday.

  • *Novartis to seek approval with global regulators. ZURICH, March 31- Novartis has ended a late-stage clinical trial of a chronic heart failure drug early, following strong interim results, giving the Swiss drugmaker a boost after recent setbacks to another heart failure medicine.

  • ZURICH, March 31- Swiss drugmaker Novartis is set to end a late-stage clinical trial of a chronic heart failure drug early, following strong interim results. Novartis said it would start talks with global health regulators about filing for drug for approval.

  • Nonsurgical fix could replace open-heart surgery Sunday, 30 Mar 2014 | 2:07 PM ET
    Medtronic's CoreValve Evolut

    A new study boosts fixing a bad aortic valve, the heart's main gate, without open-heart surgery.

  • WASHINGTON, March 30- A new type of heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said.

  • WASHINGTON, March 30- An experimental heart drug being developed by GlaxoSmithKline, which failed the main goal of a Phase III study of patients with chronic but well-treated heart disease, showed signs of potential benefit, the trial's co-leader said Sunday.

  • March 29- Gilead Sciences Inc, under fire for pricing a new hepatitis C drug at $1,000 a pill, has discount agreements with a number of health insurers, a company executive said in an interview.

  • March 28- Biogen Idec Inc has won U.S. approval for its long-acting hemophilia B treatment Alprolix, the U.S. Food and Drug Administration said on Friday. It affects about 4,000 people in the United States and 25,000 worldwide.

  • Biotech funds: Only for those immune to fear Friday, 28 Mar 2014 | 1:53 PM ET

    Biotech has been so hot the past two years that the sector is starting to raise red flags.

  • March 28- Idera Pharmaceuticals Inc said its lead experimental drug for the most common form of psoriasis was found to be safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial.

  • March 28- Idera Pharmaceuticals Inc said its lead experimental drug for the most common form of psoriasis was found to be safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial. The company's shares rose 40 percent to $5.40 in premarket trading on Friday.

  • March 28- Idera Pharmaceuticals Inc said its experimental drug for an inflammatory skin disease was found safe and well tolerated by patients after 12 weeks of treatment in a mid-stage trial. The company's shares rose about 40 percent to $5.40 in premarket trading on Friday.

  • *All retail supplies recalled in U.S. and Puerto Rico. LONDON, March 27- GlaxoSmithKline is recalling all supplies of its non-prescription weight-loss drug Alli in the United States and Puerto Rico after customers reported finding other pills and tablets in some bottles.

  • March 26- Some bottles of Alli, GlaxoSmithKline Plc's weight-loss drug sold over the counter in the United States, have been tampered with, and the Food and Drug Administration was investigating, the company said on Wednesday.

  • GSK reports tampering of some bottles of weight-loss drug Wednesday, 26 Mar 2014 | 10:17 AM ET

    March 26- GlaxoSmithKline Plc said some bottles of its weight-loss drug Alli bought in the United States had been tampered with and that the U.S. Food and Drug Administration was investigating. Consumers reported that some bottles bought in stores in seven states contained products other than the drug, the company said on Wednesday.

Most Popular Video

Wednesday, 16 Apr 2014 | 4:03 PM ET

Providing instant analysis to Google's quarterly numbers, with Victor Anthony, Topeka Capital Markets; Andrew Stoltmann of Stoltmann Law Offices; CNBC contributor Michael Yoshikami; "Fast Money" trader Tim Seymour; CNBC's Michelle Caruso-Cabrera and Dominic Chu.

Wednesday, 16 Apr 2014 | 12:35 PM ET

Intel CEO Brian Krzanich discusses some signs of stability in enterprise in the mature markets, and whether the emerging markets area steadying as well.

Wednesday, 16 Apr 2014 | 11:56 AM ET

Art Cashin, UBS director of floor operations, explains what played into yesterday's market reversal and tells what sectors are back in favor today.